Friday, April 21, 2017 12:59:24 PM
By ex-US collaboration, I wasn't referring to MighTy actually. I think there will be a partnership with someone like Roche on something like head and neck cancer. That's where I'm guessing we will see a big inflection point in terms of share price this year.
Interim data from the registration trial could also really help the stock if the first 23 real non-responders show a 30% response in Q4. It is possible that the "secure licensing & commercial partnerships" milestone could be referring to the registration trial and possible $ deal with MRK. But seems more likely to me at least that the milestone could be hinting more at an ex-US partnership.
Recent ONCSQ News
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 07:30:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM